China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its self-developed CDH17-targeted antibody-drug conjugate (ADC), 7MW4911, has received clinical trial application acceptance from China’s National Medical Products Administration (NMPA) and an IND Acknowledgment Letter from the US Food and Drug Administration (FDA).
Innovative ADC Design
7MW4911 is an innovative ADC drug targeting cadherin-17 (CDH17), developed using Mabwell’s proprietary DDC antibody conjugation technology platform. The drug integrates three core components:
- A highly specific anti-CDH17 monoclonal antibody (Mab0727) with rapid internalization and moderate affinity across species (human/monkey).
- A novel cleavable linker designed to ensure controlled drug release.
- A proprietary DNA topoisomerase I inhibitor payload (MF-6), engineered to overcome multidrug resistance mechanisms.
Enhanced Antitumor Activity
The MF-6 payload significantly enhances antitumor activity through excellent plasma stability, controlled drug release, and a potent bystander effect. These features position 7MW4911 as a promising therapeutic option for CDH17-expressing cancers.-Fineline Info & Tech
